{
    "id": 3106,
    "fullName": "EGFR A289V",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EGFR A289V lies within the extracellular domain of the Egfr protein (PMID: 17177598). A289V confers a gain of function on Egfr, as indicated by increased ligand-independent Egfr phosphorylation and is transforming in cell culture (PMID: 17177598, PMID: 29533785).",
            "references": [
                {
                    "id": 1877,
                    "pubMedId": 17177598,
                    "title": "Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17177598"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "A289V",
    "createDate": "02/15/2015",
    "updateDate": "09/12/2018",
    "referenceTranscriptCoordinates": {
        "id": 135519,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55154129C>T",
        "cDna": "c.866C>T",
        "protein": "p.A289V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15758,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, icotinib treatment resulted in a 5-month partial response in a single Chinese patient with metastatic non-small cell lung cancer harboring the mutation, EGFR A289V, which was identified in circulating DNA (PMID: 30572543).",
            "molecularProfile": {
                "id": 2929,
                "profileName": "EGFR A289V"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13741,
                    "pubMedId": 30572543,
                    "title": "Nonsmall cell lung cancer with rare exon 7 p.A289V mutation in the EGFR gene responds to Icotinib treatment: A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30572543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17203,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, icotinib treatment resulted in a 4-month partial response in a single East Asian patient with non-small cell lung cancer harboring the mutation, EGFR A289V (J Clin Oncol 37, 2019 (suppl; abstr e13000)).",
            "molecularProfile": {
                "id": 2929,
                "profileName": "EGFR A289V"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15227,
                    "pubMedId": null,
                    "title": "An EGFR extracellular domain mutation data in the East Asian non-small cell lung cancer populations and response to icotinib: A multicenter study.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e13000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12408,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR A289V were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 2929,
                "profileName": "EGFR A289V"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12411,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR A289V were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 2929,
                "profileName": "EGFR A289V"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12410,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR A289V were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating decreased cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 2929,
                "profileName": "EGFR A289V"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6917,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR A289V in culture (PMID: 17177598).",
            "molecularProfile": {
                "id": 2929,
                "profileName": "EGFR A289V"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1877,
                    "pubMedId": 17177598,
                    "title": "Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17177598"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12409,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR A289V were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 2929,
                "profileName": "EGFR A289V"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2929,
            "profileName": "EGFR A289V",
            "profileTreatmentApproaches": [
                {
                    "id": 17919,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR A289V"
                },
                {
                    "id": 17917,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR A289V"
                },
                {
                    "id": 17918,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR A289V"
                },
                {
                    "id": 17921,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR A289V"
                },
                {
                    "id": 17920,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR A289V"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135519,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55154129C>T",
            "cDna": "c.866C>T",
            "protein": "p.A289V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 135520,
            "transcript": "NM_201284",
            "gDna": "chr7:g.55154129C>T",
            "cDna": "c.866C>T",
            "protein": "p.A289V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 135521,
            "transcript": "NM_201282",
            "gDna": "chr7:g.55154129C>T",
            "cDna": "c.866C>T",
            "protein": "p.A289V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 135522,
            "transcript": "NM_201283",
            "gDna": "chr7:g.55154129C>T",
            "cDna": "c.866C>T",
            "protein": "p.A289V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}